Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY-NC-ND 4.0International Journal of Oncology

Research progress of SPP1 in cancer regulation: Tumorigenesis, metastasis, tumor microenvironment, immunity and therapeutic targets (Review)

4 affiliations
  1. 1College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, P.R. China
  2. 2Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China
  3. 3Department of Gynecological Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China
  4. 4Xianghu Laboratory, Hangzhou, Zhejiang 311231, P.R. China

Abstract

Secreted phosphoprotein 1 (SPP1, also known as osteopontin, OPN) is a multifunctional matricellular glycoprotein that is aberrantly overexpressed in nearly all major human malignancies. It functions as a central signaling hub that drives tumor initiation, sustains cancer stemness, accelerates invasion and metastasis, remodels the tumor microenvironment (TME), and mediates immune evasion. SPP1 exerts its oncogenic effects by binding to integrin family receptors (αvβ3, αvβ5, α5β1) and CD44 variants, thereby activating canonical oncogenic signaling cascades including PI3K/AKT, NF-κB, MAPK/ERK and Wnt/β-catenin. Beyond cancer-cell-autonomous functions, SPP1 orchestrates a complex immunosuppressive TME by modulating tumor-associated macrophages, cancer-associated fibroblasts, myeloid-derived suppressor cells, regulatory T cells (Tregs) and cytotoxic T-cell activity. Preclinical studies have validated SPP1 as a promising therapeutic target, with strategies including neutralizing antibodies, RNA aptamers, small-molecule inhibitors, RNA interference and combination immunotherapy showing potent antitumor efficacy. The present review systematically summarizes the molecular basis of SPP1, its receptor-mediated signaling, multifaceted regulatory roles in tumor biology, TME remodeling, immune suppression and advances in SPP1-targeted therapy. Current challenges, emerging concepts and future directions to translate SPP1-targeted interventions into clinical practice for cancers were further discussed.

Related

  1. Progress in research on gut microbiota regulation of tumorigenesis, progression, and therapeutic response via inflammatory cytokines
    Yan Liu, Dan Zang, Jun Chen
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMCCrossrefEurope PMC
  2. DVT-primed neutrophils reshape the brain microenvironment to promote brain metastasis
    S. Endo, D. Rujchanarong, K. Keeran +17
    bioRxivPreprintCC0Full textMolecular biology & gene regulationbioRxiv
  3. Biochemical Characteristics of the Vascular Microenvironment in Pathological Conditions and Precision Therapeutic Strategies
    LI Bo-Chao
    Shengwu huaxue yu shengwu wuli jinzhanPeer-reviewedCC BY-NCFull textMolecular biology & gene regulationDOAJ
  4. BATF condensation drives gastric cancer metastasis via chromatin association and transcriptional regulation
    Tong Feng, Zhaomin Deng, Kai Deng +8
    Cell ReportsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationDOAJCrossref
  5. Single-cell and bulk transcriptomic analysis of inflammation-metabolism programs and the tumor microenvironment of colorectal cancer liver metastasis
    Zhen Ma, Wen Jiang, Jian Zhang +4
    Translational OncologyPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationPMC
BibTeX
@article{xia2026research,
  title = {{Research progress of SPP1 in cancer regulation: Tumorigenesis, metastasis, tumor microenvironment, immunity and therapeutic targets (Review)}},
  author = {Yujun Xia and Dong Han and Song Tang and Huimin Yang and Rongjie Zhao and Beibei Cao and Peixi Zhu and Aiqin Shi and Huacheng Luo},
  journal = {International Journal of Oncology},
  year = {2026},
  month = oct,
  doi = {10.3892/ijo.2026.5949},
  url = {https://doi.org/10.3892/ijo.2026.5949},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Research progress of SPP1 in cancer regulation: Tumorigenesis, metastasis, tumor microenvironment, immunity and therapeutic targets (Review)
AU  - Yujun Xia
AU  - Dong Han
AU  - Song Tang
AU  - Huimin Yang
AU  - Rongjie Zhao
AU  - Beibei Cao
AU  - Peixi Zhu
AU  - Aiqin Shi
AU  - Huacheng Luo
PY  - 2026
DA  - 2026/10/14
JO  - International Journal of Oncology
DO  - 10.3892/ijo.2026.5949
UR  - https://doi.org/10.3892/ijo.2026.5949
AB  - Secreted phosphoprotein 1 (SPP1, also known as osteopontin, OPN) is a multifunctional matricellular glycoprotein that is aberrantly overexpressed in nearly all major human malignancies. It functions as a central signaling hub that drives tumor initiation, sustains cancer stemness, accelerates invasion and metastasis, remodels the tumor microenvironment (TME), and mediates immune evasion. SPP1 exerts its oncogenic effects by binding to integrin family receptors (αvβ3, αvβ5, α5β1) and CD44 variants, thereby activating canonical oncogenic signaling cascades including PI3K/AKT, NF-κB, MAPK/ERK and Wnt/β-catenin. Beyond cancer-cell-autonomous functions, SPP1 orchestrates a complex immunosuppressive TME by modulating tumor-associated macrophages, cancer-associated fibroblasts, myeloid-derived suppressor cells, regulatory T cells (Tregs) and cytotoxic T-cell activity. Preclinical studies have validated SPP1 as a promising therapeutic target, with strategies including neutralizing antibodies, RNA aptamers, small-molecule inhibitors, RNA interference and combination immunotherapy showing potent antitumor efficacy. The present review systematically summarizes the molecular basis of SPP1, its receptor-mediated signaling, multifaceted regulatory roles in tumor biology, TME remodeling, immune suppression and advances in SPP1-targeted therapy. Current challenges, emerging concepts and future directions to translate SPP1-targeted interventions into clinical practice for cancers were further discussed.
SN  - 1019-6439
SN  - 1791-2423
ER  -